

Press Release

**SHAREHOLDERS' MEETING HELD TODAY APRIL 29
IN FIRST CALL, IN ADDITION TO BOARD OF DIRECTORS' MEETING**

- *2021 Financial Statements approved, which report a Profit of Euro 8,141,357*
 - *Distribution of an ordinary dividend of Euro 0.10 per share approved*
 - *Legal audit for the 2022-2030 nine-year period granted to Ernst & Young Spa*
- *Adjustments to the By-Laws in line with regulatory requirements approved by the Board of Directors*

Istrana (TV), April 29, 2022 — Labomar (Ticker: LBM), an Italian-based international nutraceutical enterprise, announces that the Shareholders' Meeting which approved the 2021 Financial Statements of the company was held today, reporting a Net profit of Euro 8,141,357, together with the Directors' Report, in addition to the Annual Report on the pursuit of the common benefit as per the Stability Law 208/2015 ("2021 Impact Report").

The Shareholders' Meeting then approved, on the proposal of the Board of Directors, the allocation of the Net profit and the distribution to shareholders of an ordinary dividend of Euro 0.10 for each of the entitled shares.

The coupon date shall be May 9, with dividend record date of May 10 and payout on May 11.

The Shareholders' Meeting also approved, on the reasoned proposal of the Board of Statutory Auditors, the granting of the legal audit appointment of the Labomar Spa financial statements, for the 2022-2030 period, to the Independent Audit Firm Ernst & Young SpA, in accordance with the applicable regulation for general issuers of securities as "entities subject to the intermediate regime", a status which Labomar assumed from January 1, 2022.

The Board of Directors in addition considered, among other matters, the adjustment of the By-Laws in line with regulatory requirements, including those applicable to general issuers of shares, with interesting amendments in particular to Articles 6.3, 10.3 and 25.3.

The Board then updated the "Policy for the management of transactions by persons exercising administration, control or management of the financial instruments of Labomar Spa traded on the Euronext Growth Milan market" and the "Inside information communication policy".

Finally, the Board of Directors approved the review of the Ethics Code, supplementing the definitions of the Mission and of the Values and better specifying the commitments assumed by the company in terms of human rights and the focus on the individual, in line with the By-Laws and the B Corp certification process that Labomar is undertaking.

The company announces that copies of the 2021 Financial Statements of Labomar Spa, of the Labomar Group 2021 Consolidated Financial Statements and the Labomar Spa 2021 Impact Report (these latter two in their Italian and English versions) are available at the registered office, in addition to the company website Labomar Spa www.labomar.com, in the "Governance / Shareholders' Meeting" and "Investors / Results and Press Releases" sections.

This press release is published on the "1INFO" platform on the www.1info.it site, in addition to the Labomar Spa website www.labomar.com, in the "Governance / Shareholders' Meeting" and "Investors / Results and Press Releases" sections.

The minutes of the Shareholders' Meeting and the updated By-Laws shall be published in accordance with the applicable regulation, also on the company website www.labomar.com, respectively in the "Governance / Shareholders' Meeting" and "Governance / Governance Documents" sections.

The updated texts of the policies and of the Ethics Code are published on the Labomar website www.labomar.com, in the "Governance / Governance Documents" section.

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA's revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39 335 7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum - +39 02 9049 2525 - ecm@mediolanum.it